scholarly journals The effect of socioeconomic status, race, and insurance type on newly diagnosed metastatic prostate cancer in the United States (2004–2013)

2018 ◽  
Vol 36 (3) ◽  
pp. 91.e1-91.e6 ◽  
Author(s):  
Adam B. Weiner ◽  
Richard S. Matulewicz ◽  
Jeffrey J. Tosoian ◽  
Joseph M. Feinglass ◽  
Edward M. Schaeffer
Cancer ◽  
2011 ◽  
Vol 118 (5) ◽  
pp. 1260-1267 ◽  
Author(s):  
Sandip M. Prasad ◽  
Xiangmei Gu ◽  
Stuart R. Lipsitz ◽  
Paul L. Nguyen ◽  
Jim C. Hu

2016 ◽  
Vol 9 (3) ◽  
pp. 738-746 ◽  
Author(s):  
Gbeminiyi Samuel ◽  
Amir Isbell ◽  
Onyekachi Ogbonna ◽  
Hasan Iftikhar ◽  
Susmita Sakruti ◽  
...  

Prostate cancer is the most commonly diagnosed visceral cancer in the United States. A majority of cases exhibit an insidious course and nonaggressive tumor behavior. Prostate cancer can manifest as lesions which remain localized, regionally invading or metastasize to lymph nodes, bones, and lungs. Here, we report a unique case of metastatic prostate cancer to the right upper mediastinum, presenting as a paravertebral mass within 2 years of initial tissue diagnosis. Paravertebral spread has not been described for prostate cancer, and herein, we discuss the clinical presentation, diagnostic workup, and possible therapeutic options available in light of the literature.


2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 180-180 ◽  
Author(s):  
T. Mitin ◽  
M. Chen ◽  
B. J. Moran ◽  
D. E. Dosoretz ◽  
M. J. Katin ◽  
...  

180 Background: African American (AA) men present more frequently with high-grade prostate cancer (PCa) and are also more likely to have diabetes mellitus (DM). We evaluated whether there is an independent association between DM and the risk of high-grade PCa in men diagnosed with PCa, adjusting for the known predictors of high-grade PCa including AA race. Methods: Between 1991 and 2009 15,377 men newly diagnosed with PCa and treated at 1 of 26 centers, were analyzed in 2 cohorts. Multivariable logistic regression was performed to evaluate whether a diagnosis of DM was associated with the odds of Gleason 7 or 8 to 10 PCa, adjusting for AA race, advancing age, PSA level, and DRE findings. Results: AA men (AOR, 1.87; 95% CI, 1.04-3.37, P=0.04) and non-AA men (AOR, 1.61; 95% CI, 1.34-1.93; P<0.001) with diabetes were more likely to have GS 8 to 10 versus GS 6 or less PCa, compared to non-diabetic men. AA as compared to non-AA race was not significantly associated with the odds of having GS 8 to 10 as compared to 6 or less PCa, both in men with a diagnosis of DM (AOR, 1.47; 95% CI, 0.87-2.50; P=0.15) and without DM (AOR, 1.27; 95% CI, 0.92-1.74, P=0.14). AA race, however (AOR, 1.37; 95% CI, 1.17-1.60, P<0.001), but not DM (AOR 1.09; 95% CI, 0.97-1.22, P=0.16), was associated with GS 7 versus 6 or less PCa. Conclusions: A diagnosis of DM is a risk factor for presenting with Gleason 8 to 10 PCa independent of race. [Table: see text] No significant financial relationships to disclose.


2016 ◽  
Vol 19 (4) ◽  
pp. 395-397 ◽  
Author(s):  
A B Weiner ◽  
R S Matulewicz ◽  
S E Eggener ◽  
E M Schaeffer

2021 ◽  
Vol Volume 13 ◽  
pp. 9127-9137
Author(s):  
Eloisa de Sá Moreira ◽  
David Robinson ◽  
Stephanie Hawthorne ◽  
Linda Zhao ◽  
Madelyn Hanson ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4951
Author(s):  
Umang Swami ◽  
Jennifer Anne Sinnott ◽  
Benjamin Haaland ◽  
Nicolas Sayegh ◽  
Taylor Ryan McFarland ◽  
...  

Background: Both novel hormonal therapies and docetaxel are approved for treatment of metastatic prostate cancer (mPC; in castration sensitive or refractory settings). Present knowledge gaps include lack of real-world data on treatment patterns in patients with newly diagnosed mPC, and comparative effectiveness of novel hormonal therapies (NHT) versus docetaxel after treatment with a prior NHT. Methods: Herein we extracted patient-level data from a large real-world database of patients with mPC in United States. Utilization of NHT or docetaxel for mPC and comparative effectiveness of an alternate NHT versus docetaxel after one prior NHT was evaluated. Comparative effectiveness was examined via Cox proportional hazards model with propensity score matching weights. Each patient’s propensity for treatment was modeled via random forest based on 22 factors potentially driving treatment selection. Results: The majority of patients (54%) received only androgen deprivation therapy for mPC. In patients treated with an NHT, alternate NHT was the most common next therapy and was associated with improved median overall survival over docetaxel (abiraterone followed by docetaxel vs. enzalutamide (8.7 vs. 15.6 months; adjusted hazards ratio; aHR 1.32; p = 0.009; and enzalutamide followed by docetaxel vs. abiraterone (9.7 vs. 13.2 months aHR 1.40; p = 0.009). Limitations of the study include retrospective design.


2018 ◽  
Vol 4 (1) ◽  
pp. 121-127 ◽  
Author(s):  
Scott P. Kelly ◽  
William F. Anderson ◽  
Philip S. Rosenberg ◽  
Michael B. Cook

Sign in / Sign up

Export Citation Format

Share Document